ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 5, 2026
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $28,242 | $(175,218) |
| Adjustments to reconcile net income (loss) to net cash flow from operating activities | ||
| Stock-based compensation | 19,371 | 15,209 |
| Depreciation and amortization | 6,390 | 5,235 |
| Accretion of note premiums/discounts | (1,215) | (5,704) |
| Realized gain on investments | (19) | — |
| Non-cash interest expense on liability related to the sale of future royalties | 7,600 | 5,415 |
| Non-cash interest expense on credit facility | 14,905 | 16,231 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (212,046) | (2,500) |
| Inventory | (451) | — |
| Prepaid expenses and other current assets | (13,182) | (592) |
| Accounts payable | 15,263 | 3,069 |
| Accrued expenses | (13,501) | (7,691) |
| Deferred revenue | 163,359 | — |
| Operating lease, net | (1,211) | (1,128) |
| Other | (24) | 1,402 |
| Net cash provided by (used in) operating activities | 13,481 | (146,272) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (2,148) | (7,516) |
| Purchases of investments | (136,933) | (33,749) |
| Proceeds from sales and maturities of investments | 115,339 | 118,175 |
| Net cash (used in) provided by investing activities | (23,742) | 76,910 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from the exercises of stock options | 5,098 | 634 |
| Proceeds from the issuance of pre-funded warrants | — | 25,000 |
| Payments of debt issuance costs | — | (5,000) |
| Proceeds from the issuance of common stock, net of issuance costs paid | 46,832 | — |
| Repayments of credit facility | (66,680) | — |
| Net cash (used in) provided by financing activities | (14,750) | 20,634 |
| Net decrease in cash, cash equivalents and restricted cash | (25,011) | (48,728) |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 106 | (68) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||
| BEGINNING OF PERIOD | 226,548 | 102,685 |
| END OF PERIOD | $201,643 | $53,889 |
| Supplemental disclosure of cash flows: | ||
| Income taxes paid | $(9,907) | $(11) |
| Supplemental disclosure of non-cash investing activities: | ||
| Capital expenditures included in accrued expenses | $159 | $2,574 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.